Pfizer (PFE) EPS (Basic) (2009 - 2026)

Pfizer (PFE) has reported EPS (Basic) for 18 consecutive years, with -$0.04 the latest figure, recorded in Q2 2026.

• On a quarterly basis, EPS (Basic) fell 108.11% year-over-year to -$0.04 in Q2 2026; TTM through Jun 2026 was $0.77, a 67.92% decrease from a year earlier, with the FY2025 full-year figure at $1.37, down 3.44% from the prior year.
• EPS (Basic) was -$0.04 for Q2 2026 at Pfizer, down from $0.47 in the prior quarter.
• Over five years, EPS (Basic) peaked at $1.77 in Q3 2022 and troughed at -$0.6 in Q4 2023.
• A 5-year average of $0.55 and a median of $0.52 in 2025 frame the typical range for EPS (Basic).
• Across the five-year window, EPS (Basic) surged 5979.61% in 2025 and plunged 108.11% in 2026, its largest moves.
• Over 5 years, EPS (Basic) stood at $1.77 in 2022, then slumped by 133.6% to -$0.6 in 2023, then soared by 326.18% to $1.35 in 2024, then tumbled by 121.43% to -$0.29 in 2025, then jumped by 85.53% to -$0.04 in 2026.
• The last three EPS (Basic) figures came in at -$0.04 (Q2 2026), $0.47 (Q1 2026), and -$0.29 (Q4 2025), per Business Quant data.